Chimerix Inc logo

CMRX

Chimerix Inc

$2.5

Earnings Summary

Revenue
$0.02Mn
Net Profits
$-24.77Mn
Net Profit Margins
-165113.33%

Highlights

Revenue:

Chimerix Inc’s revenue fell -98.95% since last year same period to $0.02Mn in the Q1 2022. On a quarterly growth basis, Chimerix Inc has generated -67.39% fall in its revenue since last 3-months.

Net Profits:

Chimerix Inc’s net profit jumped 74.58% since last year same period to $-24.77Mn in the Q1 2022. On a quarterly growth basis, Chimerix Inc has generated 37.3% jump in its net profits since last 3-months.

Net Profit Margins:

Chimerix Inc’s net profit margin fell -2332.25% since last year same period to -165113.33% in the Q1 2022. On a quarterly growth basis, Chimerix Inc has generated -92.29% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Chimerix Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.24
EPS Estimate Current Year
-0.24

Highlights

EPS Estimate Current Quarter:

Chimerix Inc’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a 27.27% jump from last quarter’s estimates.

EPS Estimate Current Year:

Chimerix Inc’s earning per share (EPS) estimates for the current year stand at -0.24.

Key Ratios

Key ratios of the Chimerix Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.28
Return on Assets (ROA)
-0.66
Return on Equity (ROE)
-1.45
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Chimerix Inc’s earning per share (EPS) jumped 76.86% since last year same period to -0.28 in the Q1 2022. This indicates that the Chimerix Inc has generated 76.86% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Chimerix Inc’s return on assets (ROA) stands at -0.66.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Chimerix Inc’s return on equity (ROE) stands at -1.45.

Dividend Per Share (DPS):

Chimerix Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.33
-0.28
15.15%

Company Information

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The company's three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.

Organisation
Chimerix Inc
Headquarters
Durham, North Carolina, US
Employees
54
Industry
Health Technology
CEO
Michael Sherman